Ƙaddamar da Ƙananan Hanyoyi na Synthroid da Levoxyl
Ranar 23 ga watan Yunin 2004, Hukumar Kula da Abinci da Drugura ta Amirka (FDA) ta ƙaryata game da takarda ta Citizen cewa Abbott maker Synthroid - ya aika a cikin watan Agustan 2003 game da albarkatun halitta na levothyroxine sodium. Kamfanin ya yi iƙirarin cewa hanyoyin da za a tsara zancen halittu sun kasance kuskure ne, kuma yana iya nufin cewa samfurori na fasaha mai sauƙi zasu kasance ana daukar kwayar halitta.
FDA, duk da haka, ya juya wannan buƙatar, wadda ta buɗe kofa don samfurori levothyroxine.
Yawancin masana'antun suna jira a fuka-fuki kamar yadda kamfanonin guda uku suka sanar a ranar 24 ga Yuni, 2004 cewa sun karbi takardar izinin FDA don samfurori na levothyroxine, ciki har da:
Mylan Laboratories - wanda aka karbi yarda ga levothyroxine sodium Allunan a cikin wasu daban-daban karfi ƙarfi, jigilar versions na Synthroid.
Sandoz Inc. - AB-rated (bioequivalent) levothyroxine zuwa duka Synthroid da Levoxyl.
Kamfanin Lannett - amincewar levothyroxine na Jerome Stevens Pharmaceutical, Inc. (JSP), mai ba da sabis na Lannett, wanda ya dace da Levoxyl. Ka lura: samfurin da Jerome Stevens yayi da Lannett ya rarraba, wanda aka sayar a karkashin sunan "Unithroid", shine farkon levothyroxine wanda FDA ta yarda.
Kamar yadda za a iya sa ran, manyan kamfanoni biyu masu suna levothyroxine masana'antun a lokacin, Abbott da King, sunyi nasara don kare kayayyakin su Synthroid da Levoxyl akan wannan sabon hari na gasar cin kasuwa.
Lokacin da dukkanin kamfanoni uku suka fara amfani da kwayoyin levothyroxine a nan gaba, duka Abbott da King sun gangara a cikin farashin farashin farashin farashin kasuwa.
Mene Ne Yayi Dama akan Magunguna na Thyroid?
Na farko, rundunar Abbott na PR da kuma magungunan miyagun ƙwayoyi ba ta da karfi, sunyi wa 'yan jaridu takardun aiki tare da takardun kayan aiki da kuma tuntuɓar magunguna da likitoci don ci gaba da ƙoƙarin yin matsayi na Synthroid, ƙwayoyi na biyu da aka tsara a Amurka, da kuma asusun $ 818 a cikin tallace-tallace a 2003, a matsayin "mafi kyau" levothyroxine.
Ko da yake babu bincike don kafa wannan, kuma FDA ta bayyana wadannan kwayoyin halittu, akwai tasiri mai kyau don tallafawa, shaguna da magungunan magani ga dukan Synthroid da rarraba kwayoyin halittu. Wadannan likitoci sun bayyana wannan sakon, wanda ya shaida wa marasa lafiya cewa "sabuwar kwayoyin halitta ba ta da kyau kamar Synthroid."
Abu na biyu, kamfanonin ƙwayoyi sun daina cewa wata alama ce ta fi wani ko kuma abin da aka yi amfani da shi ya fi kyau. Har zuwa yau, binciken ɗan adam, binciken bincike mai zurfi har yanzu ba a buga ba wanda ya kwatanta tasiri da / ko kwarewa na musamman da alamu da kwayoyin halittu, kuma babu wata shaida cewa wata alama ta levothyroxine ta fi kyau, ko kuma kwayoyin halitta ba daidai ba ne da magungunan levothyroxine.
Na uku, kamfanonin inshora da HMOs sun sauya marasa lafiya da yawa zuwa ga farashi mai zurfi levothyroxine. Akwai mutane da dama a kan wadannan kwayoyi da cewa har ma da dolar dalar Amurka a kowane wata, lokacin da yawancin dubban marasa lafiya suka bunkasa, sun haifar da kudade mai yawa da waɗannan kungiyoyi zasu so su ji daɗi.